Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multi-center, open, non-intervention and observational study to Evaluate the efficacy and safety of Suganon tab. or Sugamet XR tab. in patients with Type 2 diabetes
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Patients who receive Double therapy or Insulin |
| |
| Group B | Patients who receive DPP-4 inhibitor |
| |
| Group C | Drug-naïve patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Evogliptin | Drug | Evogliptin |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in HbA1c | To assess change from baseline in HbA1c | at 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in HbA1c | To assess change from baseline in HbA1c | at 24 weeks |
| The percentage of patients with HbA1c <7.0% and <6.5% | To assess the percentage of patients with HbA1c <7.0% and <6.5% |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. The subject has a contraindication
Not provided
Not provided
Not provided
Type 2 DM patients
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jongchul Won, M.D., Ph.D. | Contact | +82-2-950-8860 | dronjc@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sanggye paik pospital | Recruiting | Seoul | Nowon-gu | 01757 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42383539 | Derived | Lee JE, Hong JH, Yu SH, Baek KH, Yu J, Lee SJ, Kim HW, Park KS, Kim JH, Min K, Lee YH, Kim KS, Song MS, Kim JH, Won JC. Role of Evogliptin for Intra-Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi-Center, Prospective, Observational Study (REVISE Study). Endocrinol Diabetes Metab. 2026 Jul;9(4):e70270. doi: 10.1002/edm2.70270. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C557982 | 4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one |
| D008687 | Metformin |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
| Evogliptin | Drug | Evogliptin |
|
|
| Metformin and Evogliptin | Drug | Metformin and Evogliptin |
|
|
| at 12 and 24 weeks |
| Change in FPG | To assess change from baseline in fasting plasma glucose (FPG) | at 12 and 24 weeks |
| D004700 | Endocrine System Diseases |